McCann FitzGerald Advises Mainstay Medical Holdings plc on an Equity Financing

We acted for our client, Mainstay Medical Holdings plc, on an equity financing that raised gross proceeds of US$108 million.

Mainstay intends to use the funds to support the company’s commercial launch of ReActiv8® in the U.S., continued expansion in Europe and Australia, additional post-market clinical studies and research, and general operations. The financing was co-led by new investors Ally Bridge Group and Sofinnova Partners, through its Crossover Fund, and also included a large, global medical device company.